Complete remission of Waldenström macroglobulinemia with azacitidine and rituximab.

Weiss L, Melchardt T, Neureiter D, Kemmerling R, Moshir S, Pleyer L, Greil R, Egle A. J Clin Oncol. 2011 Aug 20,29(24):e696-8. doi: 10.1200/JCO.2011.35.8283. Epub 2011 Jul 5.

CD44-hyaluronan interactions in the pathophysiology of chronic lymphocytic leukemia – regulation by cell activation

Girbl, T, Asslaber, D, Brachtl, G, Denk, U, Weiss, L, Naor, D, Greil, R, Hartmann, TN ONKOLOGIE. 2011, 34: 140-140.

Differential bone marrow homing capacity of VLA-4 and CD38 high expressing chronic lymphocytic leukemia cells.

Brachtl G, Sahakyan K, Denk U, Girbl T, Alinger B, Hofbauer SW, Neureiter D, Hofbauer JP, Egle A, Greil R, Hartmann TN. PLoS One. 2011,6(8):e23758. doi: 10.1371/journal.pone.0023758. Epub 2011 Aug 18.

A Combination of Fludarabine/Rituximab with Escalating Doses of Lenalidomide in Previously Untreated Chronic Lymphocytic Leukemia (CLL): The REVLIRIT CLL5 AGMT Phase I/II Study, Clinical and Exploratory Analyses of Induction Results

Egle, A, Steurer, M, Gassner, F, Geisberger, R, Melchardt, T, Weiss, L, Fridrik, MA, Thaler, J, Lang, A, Greil, R BLOOD. 2011, 118(21): 135-136.

Fludarabine modulates composition and function of the T cell pool in patients with chronic lymphocytic leukaemia.

Gassner FJ, Weiss L, Geisberger R, Hofbauer JP, Egle A, Hartmann TN, Greil R, Tinhofer I. Cancer Immunol Immunother. 2011 Jan,60(1):75-85. doi: 10.1007/s00262-010-0920-3. Epub 2010 Sep 21.

Targeting Pim-2, a novel survival protein of myeloma cells, kills malignant plasma cells

Johrer, K, Obkircher, M, Neureiter, D, Parteli, J, Hamacher, F, Merkel, O, Wacht, N, Zidorn, C, Scheideler, M, Greil, R ONKOLOGIE. 2010, 33: 187-188.

Antiapoptotic effects of p21 in arsenic trioxide induced apoptosis in CLL

Sifft, E, Asslaber, D, Schweiggl, S, Hamacher, F, Greil, R, Merkel, O ONKOLOGIE. 2010, 33: 185-185.

Non-pegylated liposomal doxorubicin in metastatic breast cancer (MBC) – Results from an Austrian post marketing surveillance programme

Steger, GG, Mlineritsch, B, Bartsch, R, Pluschnig, U, Petru, E, Peintinger, F, Sevelda, P, Greil, R ONKOLOGIE. 2010, 33: 55-55.

ADJUVANT ENDOCRINE THERAPY, ALONE OR IN COMBINATION WITH ZOLEDRONIC ACID (ZOL), IN PREMENOPAUSAL PATIENTS (PTS) WITH ENDOCRINE-RESPONSIVE EARLY BREAST CANCER (EBC): SUBGROUP ANALYSES OF ABCSG-12

Gnant, M, Mlineritsch, B, Stoeger, H, Luschin-Ebengreuth, G, Poestlberger, S, Steger, GG, Jakesz, R, Singer, CF, Eidtmann, H, Greil, R ANN ONCOL. 2010, 21: 79-79.

ABCSG-24: EFFICACY OF ANTHRACYCLINE- AND TAXANE-BASED NEOADJUVANT THERAPY +/- CAPECITABINE (C) IN TRIPLE-NEGATIVE EARLY BREAST CANCER (TNBC)

Steger, GG, Greil, R, Jakesz, R, Mlineritsch, B, Lang, A, Rudas, M, Marth, C, Stoeger, H, Singer, CF, Gnant, M ANN ONCOL. 2010, 21: 79-79.